$2.02
Werewolf Therapeutics is a biotechnology business based in the US. Werewolf Therapeutics shares (HOWL) are listed on the NASDAQ and all prices are listed in US Dollars. Werewolf Therapeutics employs 45 staff and has a trailing 12-month revenue of around $9.3 million.
Our top picks for where to buy Werewolf Therapeutics stock
How to buy Werewolf Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – HOWL. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Werewolf Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Werewolf Therapeutics stock price (NASDAQ: HOWL)
Use our graph to track the performance of HOWL stocks over time.Werewolf Therapeutics shares at a glance
Latest market close | $2.04 |
---|---|
52-week range | $1.57 - $8.19 |
50-day moving average | $2.36 |
200-day moving average | $4.25 |
Wall St. target price | $12.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.38 |
Is it a good time to buy Werewolf Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Werewolf Therapeutics price performance over time
Historical closes compared with the close of $2.04 from 2024-09-05
1 week (2024-08-30) | -5.56% |
---|---|
1 month (2024-08-07) | 19.30% |
3 months (2024-06-07) | -41.55% |
6 months (2024-03-07) | -69.78% |
1 year (2023-09-07) | -20.93% |
---|---|
2 years (2022-09-07) | -72.09% |
3 years (2021-09-07) | 18.83 |
5 years (2019-09-03) | N/A |
Werewolf Therapeutics financials
Revenue TTM | $9.3 million |
---|---|
Gross profit TTM | $-37,360,000 |
Return on assets TTM | -21.51% |
Return on equity TTM | -48.27% |
Profit margin | 0% |
Book value | $2.38 |
Market Capitalization | $94.4 million |
TTM: trailing 12 months
Werewolf Therapeutics share dividends
We're not expecting Werewolf Therapeutics to pay a dividend over the next 12 months.
Werewolf Therapeutics share price volatility
Over the last 12 months, Werewolf Therapeutics's shares have ranged in value from as little as $1.574 up to $8.1939. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Werewolf Therapeutics's is 0.46. This would suggest that Werewolf Therapeutics's shares are less volatile than average (for this exchange).
To put Werewolf Therapeutics's beta into context you can compare it against those of similar companies.
- Curis (CRIS.US): 3.354
- Applied Therapeutics (APLT.US): 2.031
- AVEO Pharmaceuticals (AVEO.US): 0.977
Werewolf Therapeutics overview
Werewolf Therapeutics, Inc. , a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Frequently asked questions
What percentage of Werewolf Therapeutics is owned by insiders or institutions?Currently 6.232% of Werewolf Therapeutics shares are held by insiders and 74.221% by institutions. How many people work for Werewolf Therapeutics?
Latest data suggests 45 work at Werewolf Therapeutics. When does the fiscal year end for Werewolf Therapeutics?
Werewolf Therapeutics's fiscal year ends in December. Where is Werewolf Therapeutics based?
Werewolf Therapeutics's address is: 200 Talcott Ave, Watertown, MA, United States, 02472 What is Werewolf Therapeutics's ISIN number?
Werewolf Therapeutics's international securities identification number is: US95075A1079
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question